Peppermint Oil
Also sold as: Peppermint · Mentha piperita oil · Enteric-coated peppermint oil
A menthol-containing essential oil studied mainly for IBS symptoms. Enteric-coated oral capsules, topical preparations and inhaled aroma have separate evidence and safety profiles.
Energy
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Energy: A seven-person crossover trial found no aerobic-capacity benefit after 10 days; this small null trial cannot establish universal ineffectiveness.
REALITY CHECK // IBS meta-analyses support a possible symptomatic benefit, with very low certainty in the 2022 review and more adverse events than placebo. Tea is not equivalent to enteric-coated oil, dyspepsia evidence largely concerns peppermint plus caraway, and a small controlled exercise trial was null.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No formal EFSA/NIH upper intake level is established in this dossier. Trial doses are not safety ceilings. High-dose oil can cause nausea, vomiting, dizziness and ataxia; long-term safety is uncertain.
Summary
For adult IBS, meta-analyses suggest symptom and pain relief, but the 2022 review rated certainty very low. This is symptom management, not a cure for IBS or SIBO. Peppermint plus caraway data in functional dyspepsia cannot establish peppermint-only efficacy.
Mechanism
Menthol relaxes gastrointestinal smooth muscle; it can also relax the lower esophageal sphincter and worsen reflux. Topical cooling involves TRPM8 signaling and is a different route.
Typical studied dose
The dossier reports enteric-coated oil about 180-400 mg per dose up to three times daily for several weeks; typical capsule descriptions are about 180-225 mg. Topical headache studies used approximately 10% oil in ethanol, not an oral dose.
Upper limit
No formal EFSA/NIH upper intake level is established in this dossier. Trial doses are not safety ceilings. High-dose oil can cause nausea, vomiting, dizziness and ataxia; long-term safety is uncertain.
Popular stacks with Peppermint Oil
Not enough stack data yet. A combination with Peppermint Oil appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Enteric-coated peppermint oil Best for: Adult IBS symptom evidence. |
Extract weight · marker not quantified | 540–1200 mg | Delayed intestinal release; compare the full oil mass, not absorbed menthol. Less gastric release than uncoated oil, but heartburn still occurs. |
Studied standard [FORM // REFERENCE] Daily comparison uses the dossier range of 180-400 mg up to three times daily. Marker percentage is not specified; zero means unknown, not absent. |
| Uncoated oral peppermint oil Best for: Product comparison only; no validated matching oral trial target. |
Unstandardized: active content unknown | no comparable trial range | Releases in the stomach; not interchangeable with enteric-coated delivery. Greater reflux/heartburn risk; anal burning can occur. |
Caution [FORM // CAUTION] Do not transfer the enteric-coated IBS dose or effect to drops. |
| Peppermint leaf tea Best for: Traditional digestive comfort, not an equivalent IBS trial product. |
Unstandardized: active content unknown | no comparable trial range | Oil content and release site vary; no verified oil-mass conversion. Usually mild, but reflux remains possible. |
Caution [FORM // CAUTION] No declared extraction ratio or marker; calculator cannot infer oil content. |
| Topical peppermint oil, approximately 10% in ethanol Best for: Small tension-type headache trials. |
Unstandardized: active content unknown | no comparable trial range | Local skin application, not oral bioavailability. Not applicable to oral tolerance; skin irritation possible. |
Caution [FORM // CAUTION] The approximately 10% topical solution is not a supplement conversion or a validated oral mg target. Do not swallow or apply near infant airways. |
Common label traps
- TRAP_01 // TEA EQUALS ENTERIC OIL
Tea has lower, variable oil content and a different delivery site; the IBS evidence does not transfer. - TRAP_02 // PEPPERMINT CURES IBS OR SIBO
Trials measure symptom relief, not eradication of SIBO or a cure. - TRAP_03 // OPENS THE LUNGS FOR RUNNING
The seven-person crossover trial showed VO2peak 3.54 versus 3.52 L/min and time to exhaustion 583 versus 587 seconds after 10 days: no detected benefit.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- IBS symptoms Limited · benefit
2022 meta-analysis: 10 RCTs, n=1030, risk of no global improvement RR 0.65 (95% CI 0.43-0.98), NNT 4; persistent pain RR 0.76 (0.62-0.93), NNT 7. Certainty very low. Adverse events RR 1.57 (1.04-2.37), mainly reflux/heartburn. The 2019 analysis of 12 RCTs, n=835, reported global improvement RR 2.39 (1.93-2.97) and pain improvement RR 1.78 (1.43-2.20), NNT 3-4; different endpoint direction must not be confused.
PMID 35942669 PMID 30654773 - Functional dyspepsia: combination only Limited · benefit
Peppermint plus caraway: n=114, four-week RCT showed pain improvement 7.6±4.8 versus 3.4±4.3 and discomfort 3.6±2.5 versus 1.3±2.1, P<0.001. Reviews support the combination; a 1999 trial compared it with cisapride. Manufacturer sponsorship and no isolated peppermint effect limit inference.
PMID 28695660 PMID 31827561 PMID 36502789 PMID 10604046 - Tension-type headache: topical route Limited · benefit
Small studies of topical oil, including a 1996 comparison with paracetamol 1000 mg and a youth trial, suggest relief. These are not anxiety or oral-capsule trials.
PMID 8805113 PMID 7954745 PMID 37730471 - Nausea: inhaled route Limited · benefit
Cancer/postoperative reviews show low-quality, heterogeneous evidence. In the 2004 RCT, peppermint, isopropyl alcohol and placebo were equally effective, suggesting nonspecific effects; the cardiac-surgery trial was positive.
PMID 38330531 PMID 29523018 PMID 14770380 PMID 32891278 - Aerobic performance Limited · no benefit
Seven-person crossover trial after 10 days: VO2peak 3.54 versus 3.52 L/min; exhaustion time 583 versus 587 seconds. No detected improvement, with substantial uncertainty from the tiny sample.
PMID 28177705
Reader questions
Capsules, drops or tea for IBS?
The supporting trials principally used enteric-coated capsules. Neither tea nor uncoated drops has a validated equivalence.
Can it worsen reflux when I also have IBS?
Yes. Smooth-muscle relaxation can worsen reflux or heartburn; coating reduces gastric exposure without eliminating the risk. Review concurrent acid suppression.
How much and when?
Trial exposures are summarized above, not prescribed here. Follow the specific enteric product instructions and discuss refractory abdominal pain or combined IBS/reflux with a clinician.
Is continuous long-term use established?
No. IBS studies generally ran 2-12 weeks, with inadequate evidence for years of use.
Stack interactions
- Caution CYP3A4 substrates, including felodipine [CAUTION // REVIEW_CONTEXT]
In a human crossover study, 600 mg oil increased felodipine AUC to about 140%; other-substrate effects require individual review.
PMID 12235445 - Caution PPIs and antacids [CAUTION // REVIEW_CONTEXT]
Higher gastric pH may cause premature release from enteric coatings. The dossier suggests about two-hour spacing, but PPI acid suppression persists; obtain product-specific advice. - Caution Caraway and other carminative herbs [CAUTION // REVIEW_CONTEXT]
Peppermint plus caraway has its own dyspepsia evidence; its effects cannot be assigned to peppermint alone.
PMID 28695660
Red flags: interactions and who should avoid it
Interactions
A 600 mg peppermint-oil exposure increased felodipine AUC to about 140% in a human crossover study; review CYP3A4 substrates, particularly narrow-therapeutic-index medicines. Acid suppressants/antacids may disrupt enteric release; review the specific medicine and product instructions rather than assuming spacing solves PPI effects. CYP2C effects are a weaker hypothesis.
Avoid or ask a doctor first if
Reflux, hiatal hernia, gallstones or biliary obstruction warrant review; enteric coating does not eliminate reflux. Pregnancy/lactation and severe liver disease lack adequate safety data. Never apply menthol to the face or nose of infants/young children because laryngospasm and apnea are possible. Stop for worsening reflux or neurologic symptoms.
Sources (PubMed, 16)
- Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome.
PMID 35942669 · 2022 · Systematic review and meta-analysis2022 meta-analysis: 10 RCTs, n=1030, risk of no global improvement RR 0.65 (95% CI 0.43-0.98), NNT 4; persistent pain RR 0.76 (0.62-0.93), NNT 7. Certainty very low. Adverse events RR 1.57 (1.04-2.37), mainly reflux/heartburn. The 2019 analysis of 12 RCTs, n=835, reported global improvement RR 2.39 (1.93-2.97) and pain improvement RR 1.78 (1.43-2.20), NNT 3-4; different endpoint direction must not be confused. Delayed intestinal release; compare the full oil mass, not absorbed menthol. Daily comparison uses the dossier range of 180-400 mg up to three times daily. Marker percentage is not specified; zero means unknown, not absent.
- The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data.
PMID 30654773 · 2019 · Systematic review and meta-analysis2022 meta-analysis: 10 RCTs, n=1030, risk of no global improvement RR 0.65 (95% CI 0.43-0.98), NNT 4; persistent pain RR 0.76 (0.62-0.93), NNT 7. Certainty very low. Adverse events RR 1.57 (1.04-2.37), mainly reflux/heartburn. The 2019 analysis of 12 RCTs, n=835, reported global improvement RR 2.39 (1.93-2.97) and pain improvement RR 1.78 (1.43-2.20), NNT 3-4; different endpoint direction must not be confused. Delayed intestinal release; compare the full oil mass, not absorbed menthol. Daily comparison uses the dossier range of 180-400 mg up to three times daily. Marker percentage is not specified; zero means unknown, not absent.
- A randomized placebo-controlled trial on the effects of Menthacarin, a proprietary peppermint- and caraway-oil-preparation, on symptoms and quality of life in patients with functional dyspepsia.
PMID 28695660 · 2017 · Randomized controlled trialPeppermint plus caraway: n=114, four-week RCT showed pain improvement 7.6±4.8 versus 3.4±4.3 and discomfort 3.6±2.5 versus 1.3±2.1, P<0.001. Reviews support the combination; a 1999 trial compared it with cisapride. Manufacturer sponsorship and no isolated peppermint effect limit inference. Peppermint plus caraway has its own dyspepsia evidence; its effects cannot be assigned to peppermint alone.
- A Combination of Peppermint Oil and Caraway Oil for the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis.
PMID 31827561 · 2019 · Systematic review and meta-analysisPeppermint plus caraway: n=114, four-week RCT showed pain improvement 7.6±4.8 versus 3.4±4.3 and discomfort 3.6±2.5 versus 1.3±2.1, P<0.001. Reviews support the combination; a 1999 trial compared it with cisapride. Manufacturer sponsorship and no isolated peppermint effect limit inference.
- Menthacarin, a Proprietary Peppermint Oil and Caraway Oil Combination, Improves Multiple Complaints in Patients with Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis.
PMID 36502789 · 2023 · Systematic review and meta-analysisPeppermint plus caraway: n=114, four-week RCT showed pain improvement 7.6±4.8 versus 3.4±4.3 and discomfort 3.6±2.5 versus 1.3±2.1, P<0.001. Reviews support the combination; a 1999 trial compared it with cisapride. Manufacturer sponsorship and no isolated peppermint effect limit inference.
- Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study.
PMID 10604046 · 1999 · Randomized controlled trialPeppermint plus caraway: n=114, four-week RCT showed pain improvement 7.6±4.8 versus 3.4±4.3 and discomfort 3.6±2.5 versus 1.3±2.1, P<0.001. Reviews support the combination; a 1999 trial compared it with cisapride. Manufacturer sponsorship and no isolated peppermint effect limit inference.
- [Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type].
PMID 8805113 · 1996 · Randomized controlled trialSmall studies of topical oil, including a 1996 comparison with paracetamol 1000 mg and a youth trial, suggest relief. These are not anxiety or oral-capsule trials. Local skin application, not oral bioavailability. The approximately 10% topical solution is not a supplement conversion or a validated oral mg target. Do not swallow or apply near infant airways.
- Effect of peppermint and eucalyptus oil preparations on neurophysiological and experimental algesimetric headache parameters.
PMID 7954745 · 1994 · Randomized controlled trialSmall studies of topical oil, including a 1996 comparison with paracetamol 1000 mg and a youth trial, suggest relief. These are not anxiety or oral-capsule trials. Local skin application, not oral bioavailability. The approximately 10% topical solution is not a supplement conversion or a validated oral mg target. Do not swallow or apply near infant airways.
- Randomized Trial Examining Efficacy of Mentha piperita in Reducing Chronic Headache Discomfort in Youth.
PMID 37730471 · 2023 · Randomized controlled trialSmall studies of topical oil, including a 1996 comparison with paracetamol 1000 mg and a youth trial, suggest relief. These are not anxiety or oral-capsule trials.
- Effects of aromatherapy on nausea and vomiting in patients with cancer: A systematic review and meta-analysis of randomized controlled trials.
PMID 38330531 · 2024 · Systematic review and meta-analysisCancer/postoperative reviews show low-quality, heterogeneous evidence. In the 2004 RCT, peppermint, isopropyl alcohol and placebo were equally effective, suggesting nonspecific effects; the cardiac-surgery trial was positive.
- Aromatherapy for treatment of postoperative nausea and vomiting.
PMID 29523018 · 2018 · Systematic review and meta-analysisCancer/postoperative reviews show low-quality, heterogeneous evidence. In the 2004 RCT, peppermint, isopropyl alcohol and placebo were equally effective, suggesting nonspecific effects; the cardiac-surgery trial was positive.
- Aromatherapy with peppermint, isopropyl alcohol, or placebo is equally effective in relieving postoperative nausea.
PMID 14770380 · 2004 · Randomized controlled trialCancer/postoperative reviews show low-quality, heterogeneous evidence. In the 2004 RCT, peppermint, isopropyl alcohol and placebo were equally effective, suggesting nonspecific effects; the cardiac-surgery trial was positive.
- The effect of aromatherapy with peppermint essential oil on nausea and vomiting after cardiac surgery: A randomized clinical trial.
PMID 32891278 · 2020 · Randomized controlled trialCancer/postoperative reviews show low-quality, heterogeneous evidence. In the 2004 RCT, peppermint, isopropyl alcohol and placebo were equally effective, suggesting nonspecific effects; the cardiac-surgery trial was positive.
- Aerobic capacity is not improved following 10-day supplementation with peppermint essential oil.
PMID 28177705 · 2017 · Randomized controlled trialSeven-person crossover trial after 10 days: VO2peak 3.54 versus 3.52 L/min; exhaustion time 583 versus 587 seconds. No detected improvement, with substantial uncertainty from the tiny sample.
- The Use of Peppermint Oil in Gastroenterology.
PMID 36994979 · 2023 · Narrative reviewReleases in the stomach; not interchangeable with enteric-coated delivery. Do not transfer the enteric-coated IBS dose or effect to drops.
- Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo.
PMID 12235445 · 2002 · Randomized controlled trialIn a human crossover study, 600 mg oil increased felodipine AUC to about 140%; other-substrate effects require individual review.
Community comments
No approved comments yet. Comments are held for moderation.